Literature DB >> 34081253

Propofol Regulates the TLR4/NF-κB Pathway Through miRNA-155 to Protect Colorectal Cancer Intestinal Barrier.

Yuhua Gao1,2, Tao Han3, Cailing Han1, Hua Sun1, Xiaoxia Yang1, Dongmei Zhang1, Xinli Ni4.   

Abstract

Surgery for colorectal cancer (CRC) can cause damage to the intestinal mucosal barrier and lead to bacterial invasion. This study mainly analyzed whether propofol (PPF) could protect the intestinal mucosal barrier damage caused by CRC surgery, and explored its molecular mechanism. A mouse CRC model was constructed using azomethane and dextran sulfate sodium. During anesthesia, continuous intravenous injection of PPF was used for intervention. The influences of PPF on intestinal mucosal permeability and bacterial invasion were detected. The levels of microRNA (miR)-155, Toll-like receptor 4 (TLR4)/NF-κB in the intestinal mucosa, and the location of miR-155 were detected by fluorescence in situ hybridization (FISH). Mouse macrophages were used to analyze the regulation of miR-155 on the secretion of inflammatory cytokines through the TLR4/NF-κB pathway. PPF treatment promoted the expression of tight junction protein in the intestinal mucosa, protected the intestinal barrier, inhibited the translocation of intestinal bacteria, and increased the level of the beneficial bacterium Lactobacillus on the mucosal surface. In addition, PPF treatment could inhibit the expression of miR-155, TLR4/NF-KB, and reverse inflammatory response. miR-155 was expressed in macrophages of intestinal mucosa tissue. Overexpression of miR-155 promoted the nuclear translocation of NF-κB and the expression of inflammatory cytokines in macrophages. The use of VIPER to inhibit TLR4 reversed the pro-inflammatory effects of miR-155. PPF might inhibit the activation of the NF-κB pathway by downregulating miR-155 expression, thereby reducing the secretion of inflammatory cytokines. This might be the mechanism by which PPF protected the intestinal barrier of CRC surgical model mice.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Toll-like receptor 4 (TLR4)/NF-κB; colorectal cancer; intestinal barrier; microRNA-155; propofol

Mesh:

Substances:

Year:  2021        PMID: 34081253     DOI: 10.1007/s10753-021-01485-0

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  32 in total

1.  Propofol attenuates inflammatory damage on neurons following cerebral infarction by inhibiting excessive activation of microglia.

Authors:  Hang Yu; Xiaozhi Wang; Fuxin Kang; Zhile Chen; Yunxia Meng; Mingming Dai
Journal:  Int J Mol Med       Date:  2018-11-05       Impact factor: 4.101

2.  Effects of propofol on hemodynamic and inflammatory responses to endotoxemia in rats.

Authors:  T Taniguchi; K Yamamoto; N Ohmoto; K Ohta; T Kobayashi
Journal:  Crit Care Med       Date:  2000-04       Impact factor: 7.598

3.  Propofol Attenuates Inflammatory Response in LPS-Activated Microglia by Regulating the miR-155/SOCS1 Pathway.

Authors:  Xinxun Zheng; Hongbing Huang; Jianjun Liu; Minghua Li; Min Liu; Tao Luo
Journal:  Inflammation       Date:  2018-02       Impact factor: 4.092

4.  Propofol-based Total Intravenous Anesthesia Is Associated with Better Survival Than Desflurane Anesthesia in Colon Cancer Surgery.

Authors:  Zhi-Fu Wu; Meei-Shyuan Lee; Chih-Shung Wong; Chueng-He Lu; Yuan-Shiou Huang; Kuen-Tze Lin; Yu-Sheng Lou; Chin Lin; Yue-Cune Chang; Hou-Chuan Lai
Journal:  Anesthesiology       Date:  2018-11       Impact factor: 7.892

5.  Propofol attenuates inflammatory response and apoptosis to protect d-galactosamine/lipopolysaccharide induced acute liver injury via regulating TLR4/NF-κB/NLRP3 pathway.

Authors:  Zhaojian Zhang; Liang Tian; Kai Jiang
Journal:  Int Immunopharmacol       Date:  2019-11-15       Impact factor: 4.932

6.  Effects of propofol or sevoflurane anesthesia on the perioperative inflammatory response, pulmonary function and cognitive function in patients receiving lung cancer resection.

Authors:  H-T Tian; X-H Duan; Y-F Yang; Y Wang; Q-L Bai; X Zhang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-12       Impact factor: 3.507

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome.

Authors:  Lingbin Sun; Wei Ma; Wenli Gao; Yanmei Xing; Lixin Chen; Zhengyuan Xia; Zhongjun Zhang; Zhongliang Dai
Journal:  Cell Death Dis       Date:  2019-07-17       Impact factor: 8.469

9.  Antibodies to interleukin 12 abrogate established experimental colitis in mice.

Authors:  M F Neurath; I Fuss; B L Kelsall; E Stüber; W Strober
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

10.  Effects of propofol and sevoflurane on blood glucose, hemodynamics, and inflammatory factors of patients with type 2 diabetes mellitus and gastric cancer.

Authors:  Jinhui Liu; Li Yang
Journal:  Oncol Lett       Date:  2019-12-10       Impact factor: 2.967

View more
  3 in total

Review 1.  Bacterial Translocation in Gastrointestinal Cancers and Cancer Treatment.

Authors:  Keita Kouzu; Hironori Tsujimoto; Yoji Kishi; Hideki Ueno; Nariyoshi Shinomiya
Journal:  Biomedicines       Date:  2022-02-04

2.  Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation.

Authors:  Dong-Xue Lu; Feng Liu; Hua Wu; Hai-Xia Liu; Bing-Yu Chen; Jing Yan; Yin Lu; Zhi-Guang Sun
Journal:  World J Gastroenterol       Date:  2022-08-28       Impact factor: 5.374

Review 3.  Effects of propofol on macrophage activation and function in diseases.

Authors:  Shuyuan Yi; Xinyi Tao; Yin Wang; Qianqian Cao; Zhixia Zhou; Shoushi Wang
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.